AI-Driven Drug Formulation Developer

The 2nd Hefei Biomedical Innovation and Industry Conference【2nd Hefei BIIC】Will be held inSeptember 6Grand Opening, with Academician Zhigang Tian serving as the Conference Chair.
This conference plans to organizeMore Than Ten Forums, InvitationMore Than 100 Experts in Biomedical Innovation Industry, forMore than 1,000 participantsBuild a platform for learning, exchange, and cooperation. The conference will focus on the frontier of biopharmaceuticals, addressing hot topics and challenges in the research, development, and industrialization of innovative drugs such as antibody drugs, cell therapy drugs, gene therapy drugs, nucleic acid drugs, and novel vaccines. It will actively promote academic exchange, capital dialogue, and industry collaboration, exploring the development prospects and innovative trends of China's innovative drug research and industrialization, and fostering a high-quality pharmaceutical innovation ecosystem.


As a representative of a global leading "AI + drug delivery" company,Dr. Wang Wenshou, Co-founder & COO of METiS PharmaceuticalsInvited to attend this conference and will give a speech titled “AI-Driven Drug Delivery and Drug Discovery"Delivered a keynote speech titled 'Exploring the Application Prospects of Artificial Intelligence in the Field of Gene Therapy.'"

(METiS TechBio Speech Session)


The Comprehensive National Science Center for Health Research in Hefei (hereinafter referred to as "Health Research Center") is a large comprehensive scientific research platform jointly initiated by the Anhui Provincial Government and the Chinese Academy of Sciences, operating under the system and mechanisms of a national laboratory.Registered and established as a legal entity of Anhui Province's public institution in August 2021.The Greater Health Research Institute, with the mission of "source innovation and promoting dual transformation," focuses on the life health sector. It attracts innovative forces from research institutes and key enterprises in the health system of the entire province as well as the broader health industry inside and outside the province. The institute prioritizes research in areas such as immunotherapy methods for major diseases, small-molecule targeted anti-tumor drugs, novel cell therapy technologies, and related drugs. It is committed to bridging the gaps between basic research, technological innovation, and industrial innovation, forming an integrated innovation system that covers the entire chain from scientific discovery, technology development, clinical trials, pilot-scale production, to demonstration and application.The Institute is led by Tian Zhigang, an academician of the Chinese Academy of Engineering, and a recipient of the National Science Fund for Distinguished Young Scholars.Zhou Rongbin, recipient of the Science Fund, serves as the executive dean.
In accordance with the strategic layout of the Leading Group for the Construction of Hefei's Comprehensive National Science Center, hosting a biopharmaceutical brand conference with domestic and international influence is one of the core tasks of the Academy of Grand Health.
Related Reading:
Focus on "AI + Drug Delivery," METiS TechBio Completes $100 Million Series C Financing
